Please Wait...

CTX-I // C-Terminal Crosslinked Telopeptide of Type I Collagen

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

In bone, type I collagen constitute 90% of the organic matrix. Markers of bone resorption in serum or urine can be used to assess changes in bone resorption in various bone diseases or under treatment (Naylor and Eastell, 2012). Collagen in bone can be isomerized with racemization of the aspartic residues in the CTX telopeptide. The newly formed collagen is α isomerized and β isomerization occurs with aging (Garnero, 2012). In urine, the ratio between native and isomerized CTX can give an estimate of the extent of type I collagen isomerization in bone tissue (Cloos and Fledelius, 2000). Detection of α isomerized fragment in urine is an indicator of newly formed collagen degradation and can be used for detection of bone metastases or Paget’s disease and follow up of treatments. Detection of β isomerized fragments in urine or serum is an indicator of mature bone collagen degradation, like in osteoporosis.

Different manual or automated sandwich immunoassays for CTX-I with α or β isomerization are validated in Bioclinica Lab for measurement in urine or serum matrix. Results in urine are normalized with values of urine creatinine.

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

With many clinical trials slowed or terminated, investments in new technologies are difficult. Yet, a #CTMS with a… https://t.co/VRIhWWf4tE
Bioclinica (5 days ago)
With Bioclinica #CTMS, sponsors & CROs have access to a full-featured, scalable system - a single, centralized sour… https://t.co/7ACrv8cvuF
Bioclinica (1 week ago)
Now available: a DIY #EDC solution. From study start-up to close-out, Bioclinica EDC Solo is an efficient, cost-eff… https://t.co/vFhC7ITfZV
Bioclinica (2 weeks ago)
Reduce the number of user requirement iterations and UAT findings during the #IRT build process. With the agile app… https://t.co/TJt2sZlrFP
Bioclinica (2 weeks ago)
Don't compromise with manual systems and spreadsheets. As an entry-level system with phased implementation, Bioclin… https://t.co/qIpi1MESXw
Bioclinica (3 weeks ago)
According to our recent poll, 45% of respondents had neither a #CTMS nor an #eTMF system, while only 24% had both.… https://t.co/l4dKC7pBQo
Bioclinica (3 weeks ago)